Welcome to our dedicated page for Semler Scientific SEC filings (Ticker: SMLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Semler Scientific, Inc. (Nasdaq: SMLR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents cover both its healthcare operations and its Bitcoin treasury activities, offering investors insight into how the company reports revenues and expenses from its medical device and software business alongside unrealized gains and losses from changes in the fair value of its Bitcoin holdings.
In its periodic reports, Semler Scientific presents financial statements that reflect income from operations in its healthcare segment, operating expenses such as engineering and product development, sales and marketing, and general and administrative costs, as well as line items related to digital assets. The filings detail the fair value of Bitcoin classified as intangible digital assets, changes in that fair value, and the impact on pre-tax income. They also describe capital-raising transactions, including at-the-market equity offering programs and 4.25% convertible senior notes due 2030, and provide information on stockholders’ equity.
Current reports on Form 8-K document material events such as the adoption and evolution of Semler Scientific’s Bitcoin treasury strategy, the master loan agreement with Coinbase Credit Inc. secured by Bitcoin collateral, and the agreement in principle to settle a civil investigative demand from the U.S. Department of Justice. Other 8-K filings describe a strategic plan to realign operations through headcount reductions and expense curtailment, a non-executive retention program, executive officer changes and the Agreement and Plan of Merger providing for the acquisition of Semler Scientific by Strive, Inc. in an all-stock transaction.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as segment performance, digital asset disclosures, capital structure changes and merger-related information. Investors can also use the filings to monitor topics like BTC Yield as a disclosed key performance indicator, the structure of Bitcoin-related financing arrangements and other regulatory disclosures relevant to SMLR.
Semler Scientific reported Q3 2025 results. Revenue was $7,491, down from $13,512 a year ago, as most sales came from equipment leases and lower variable-fee licenses. Despite the revenue decline, net income rose to $16,902, helped by a $28,490 change in fair value of intangible digital assets and a $1,471 gain on Bitcoin collateral revaluation. Diluted EPS was $1.07.
Intangible digital assets were carried at $539,844 at quarter end; the company held approximately 4,733 Bitcoins, excluding 315 pledged as collateral. A $20,000 short‑term Coinbase loan is secured by those 315 Bitcoins, and the related receivable for Bitcoin collateral was $35,928. In January, the company issued $100,000 of 4.25% convertible senior notes due 2030 (carrying value $96,418). Cash from financing was $320,458, including $214,964 from ATM equity sales, while investing used $284,757 largely for Bitcoin purchases.
The company paid a $29,750 DOJ settlement plus accrued interest in September and entered into a five‑year corporate integrity agreement with HHS OIG.
Strive, Inc. announced a Rule 425 communication regarding its proposed business combination with Semler Scientific. Strive has filed a Form S-4 to register Class A common stock to be issued in connection with the transaction, which will include an information statement/proxy statement/prospectus. Semler Scientific stockholders will receive definitive materials to vote on the proposed transaction.
The notice includes a forward-looking statements caution, identifies potential proxy solicitation participants, and clarifies this is not an offer or solicitation. Related documents will be available free of charge at SEC.gov and the companies’ investor relations websites.
Strive, Inc. filed a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). The notice reiterates standard forward‑looking statement cautions and directs investors to SEC filings for details.
Strive has filed a Registration Statement on Form S-4 to register Class A common stock to be issued in the transaction, with related Information Statement/Proxy Statement/Prospectus materials, including versions filed on August 6, 2025 and October 10, 2025. A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek approval of the proposed transaction.
The communication emphasizes that it is not an offer to sell or solicit an offer to buy securities. Investors are urged to read the Registration Statement and related materials when available, accessible free of charge on the SEC’s website and company investor sites.
Strive, Inc. issued a Rule 425 communication about its proposed business combination with Semler Scientific, Inc. (SMLR). Strive has filed a Registration Statement on Form S‑4 to register the Class A common stock it would issue in the transaction, which will include an information statement of Strive, a proxy statement for Semler Scientific stockholders, and a prospectus of Strive.
A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. The communication includes forward‑looking statements subject to risks and uncertainties referenced in prior SEC filings of both companies. It also notes that directors, officers, and certain employees of both companies may be deemed participants in the proxy solicitation.
This notice reiterates that it is not an offer or solicitation to sell or buy securities. Investors are urged to read the S‑4 and related materials when available on the SEC’s website and company investor sites.
Strive, Inc. issued a Rule 425 communication regarding its proposed business combination with Semler Scientific. Strive has filed a Form S-4 to register Class A common stock to be issued in connection with the transaction. The registration will include an information statement of Strive, a proxy statement of Semler Scientific, and a prospectus of Strive. A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval.
The communication contains forward-looking statement disclaimers and directs investors to SEC filings for risks and details, including Strive’s S-4 and related reports and Semler Scientific’s 10-K and 10-Qs. It notes that directors and officers of both companies may be deemed participants in the proxy solicitation and provides links to obtain documents free of charge. It also states this is not an offer to sell securities.
Strive, Inc. filed a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc. (SMLR). Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction, and a combined Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek their approval.
Investors are directed to review the Registration Statement and related materials when available on the SEC’s website and each company’s investor relations pages. The notice includes standard forward‑looking statement cautions and clarifies this is not an offer or solicitation to buy or sell securities.
Strive, Inc. reposted a communication on X in connection with its proposed business combination with Semler Scientific, Inc. (SMLR). The notice includes a forward‑looking statements caution and explains that Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction.
A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. The materials will be available free of charge on the SEC’s website and the companies’ investor sites. The communication states it is not an offer or solicitation, and identifies that Strive, Semler Scientific, and certain directors, officers, and employees may be deemed participants in the proxy solicitation for the proposed transaction.
Strive, Inc. filed a Form 425 communication regarding its proposed business combination with Semler Scientific (SMLR). Strive has filed a Registration Statement on Form S-4 to register Class A common stock to be issued in the transaction; the S-4 will include an information statement of Strive, a proxy statement of Semler, and a prospectus of Strive.
A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek their approval. The materials will be available free on the SEC’s website and the companies’ investor sites. The communication includes forward-looking statement cautions and states it is not an offer or solicitation. Directors, officers, and employees of both companies may be participants in the proxy solicitation, with their interests to be described in the forthcoming proxy/prospectus.
Strive, Inc. filed a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc. (SMLR). The notice emphasizes forward-looking statement cautions and references Strive’s Form S-4, which registers Class A common stock to be issued in connection with the transaction. A combined Information Statement/Proxy Statement/Prospectus will be provided to Semler Scientific stockholders to seek their approval.
Investors are directed to read the Registration Statement and related materials when available, accessible free of charge on the SEC’s website and each company’s investor relations pages. The communication also notes that directors and officers of both companies may be deemed participants in the proxy solicitation, with their interests to be described in the forthcoming joint materials. It reiterates a standard no offer or solicitation disclaimer, stating that any sale of securities will occur only by means of a prospectus meeting Securities Act requirements.
Strive, Inc. reposted a communication on X regarding its proposed business combination with Semler Scientific. The message emphasizes that any forward-looking statements involve risks and uncertainties.
Strive has filed a Form S‑4 to register Class A common stock to be issued in the transaction, and an Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek approval. Investors are urged to read the Registration Statement and related materials when available on the SEC website. This communication does not constitute an offer to sell securities.
FAQ
What is the current stock price of Semler Scientific (SMLR)?
What is the market cap of Semler Scientific (SMLR)?
